跳至主要内容
临床试验/EUCTR2008-001908-23-DK
EUCTR2008-001908-23-DK进行中(未招募)1 期

A randomised, double blinded, crossover study of the influence of Metoprolol on exercise induced elevation of catecholamines in healthy subjects. - MEXICHO

Rigshospitalet, Department of Clinical Pharmacology0 个研究点目标入组 30 人开始时间: 2008年6月11日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Male, age 20-30 years, non-smoker, BMI 20-25, no chronic diseases including asthma bronchiale and cardiovascular diseases of any kind. No injuries of muscoloskeleton, that prevents participants in performing a full maximal cardiopulmonary test.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Following medical products during investigational periode:
  • asthma medication, heart medication, antihistamines, antipsycotics, NSAIDs, rifampicin, chinidine, glukocorticoides, abuse of any kind.
  • Allergy and/or intolerance to metoprololsuccinate. Allergy to lactose. Abnormal ECG. Abnormal bloodsugar according to standards.

研究者

发起方
Rigshospitalet, Department of Clinical Pharmacology

相似试验

进行中(未招募)
1 期
An intervention study of the effects of a low dose and high dose hydrocortisone replacement therapy on brain functions, quality of life, risk factors for cardiovascular diseases and sensitivity in patients with adrenal insufficiency due to a previous pituitary tumor.
EUCTR2011-000864-82-NLniversity Medical Center Groningen63
进行中(未招募)
不适用
A randomised, double blind, crossover study to determine the mechanism of action of Gaviscon Advance in Gastro-Oesophageal Reflux Disease (GORD) - Gaviscon AdvanceGastro-oesophageal reflux disease (GORD)
EUCTR2010-019072-68-GBGuy's & St Thomas' NHS Foundation Trust
进行中(未招募)
不适用
A randomised, controlled, double blind study of the immunogenicity and safety of Pediacel™, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed) compared to Infanrix™–IPV+Hib when both vaccines are given to infants using a three dose immunisation schedule (Nordic schedule” 3-5-12 months)
EUCTR2005-004133-17-FISanofi Pasteur Incorporated800
进行中(未招募)
不适用
A randomised, controlled, double blind study of the immunogenicity and safety of PEDIACEL®, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed) compared to Infanrix™–IPV+Hib when both vaccines are given to infants using a three dose immunisation schedule (Nordic schedule” 3-5-12 months)PEDIACEL® is a fully liquid combination vaccine indicated for infants from 2 months of age to protect against diseases caused by 5 common pathogens: Haemophilus influenzae type b, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, and poliovirus types 1, 2 and 3.
EUCTR2005-004133-17-SESanofi Pasteur Incorporated800
已完成
2 期
The effect of cannabidiol (CBD) on simulated driving performance.
ACTRN12619001552178niversity of Sydney19